Subjective Cognitive Complaints and Objective Cognitive Impairment in Parkinson's Disease by �넀�쁺�샇 & �씠�븘�쑕
16  Copyright © 2018 Korean Neurological Association  
Background and Purpose  Subjective cognitive complaints (SCCs) are very common in 
patients with Parkinson’s disease (PD). However, the relationship between SCCs and objec-
tive cognitive impairment is still unclear. This study aimed to determine whether SCCs are 
correlated with objective cognitive performance in patients with PD.
Methods  Totals of 148 cognitively normal patients, 71 patients with mild cognitive impair-
ment (MCI), and 31 demented patients were recruited consecutively from a movement-disor-
ders clinic. Their SCCs and cognitive performances were evaluated using the Cognitive Com-
plaints Interview (CCI) and a comprehensive neuropsychological battery.
Results  The CCI score increased with age, duration of PD, and depression score, and was in-
versely correlated with cognitive performance. The association between CCI score and perfor-
mance remained significant after adjustment for the depression score, age, and duration of PD. 
The CCI score could be used to discriminate patients with dementia from cognitively normal 
and MCI patients [area under the receiver operating characteristics curve (AUC) of 0.80], but 
not patients with MCI or dementia from cognitively normal patients (AUC of 0.67).
Conclusions  SCCs as measured by the CCI are strongly correlated with objective cognitive per-
formance in patients with PD. The CCI can also be used to screen for dementia in patients with 
PD.
Key Words   Parkinson’s disease, cognition, cognitive dysfunction, dementia.
Subjective Cognitive Complaints and Objective Cognitive 
Impairment in Parkinson’s Disease
INTRODUCTION
Parkinson’s disease (PD) is diagnosed based on its motor symptoms, but cognitive impair-
ment is actually the most disabling complication in patients with PD.1 A quarter of newly 
diagnosed patients with PD have mild cognitive impairment (MCI),2,3 and approximately 
90% of PD patients eventually develop dementia.4
Subjective feelings of cognitive impairment subjective cognitive complaints (SCCs) are 
very common in the elderly, and the clinical importance of SCCs is increasing. The subjec-
tive feeling of memory impairment subjective memory complaints (SMCs) was considered 
an important component in the early concept of MCI due to Alzheimer’s disease (AD), 
and SMCs have received attention as a possible predictor for subsequent cognitive impair-
ment even in cognitively normal individuals.
Patients with PD also frequently report SCCs,5 but their clinical meaning is still unclear. 
One of the fundamental questions is whether SCCs are related to objective cognitive im-
pairment. Several studies that have explored this relationship have produced conflicting re-
sults. Three studies found an association between subjective complaints and poorer cogni-
tive performances,5-7 whereas others failed to show clear relationship8 or found that cognitive 
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scores were higher in patients with SCCs than in those with-
out SCCs.9
These studies used various methods to define SCCs, with 
some assessing SCCs using a simple yes/no question,6,8,9 and 
others using questionnaires focusing on memory symptoms 
only.5,7 However, because the pattern of cognitive impairment 
in patients with PD is not identical to that of AD, other tools 
employing questions covering various cognitive symptoms 
beyond memory complaints are needed.
The Cognitive Complaints Interview (CCI) is a validated 
questionnaire for assessing SCCs that includes questions 
about subjective complaints on memory, language, and visuo-
spatial function, daily activity, and mood. We therefore con-
sidered the CCI to be suitable for assessing SCCs in patients 
with PD.
The aim of this study was to determine the association be-
tween SCCs as measured by the CCI and objective cognitive 
performance, and to verify the ability of the CCI to detect 
objective cognitive impairment in patients with PD.
METhODS
Subjects
We consecutively recruited patients with PD from a move-
ment-disorders clinic. All of the included patients were diag-
nosed with PD based on the criteria of the UK Parkinson’s 
Disease Society Brain Bank.10 Patients who had a focal lesion 
in the basal ganglia revealed by magnetic resonance imaging 
or abnormalities in laboratory tests including thyroid func-
tion tests, vitamin B12 level, folic acid level, or the syphilis 
test were excluded from this study. Patients who experienced 
visual hallucinations or had dementia that developed before 
or within 1 year after the onset of motor symptoms were 
also excluded. Because several of the cognitive tests are not 
applicable to individuals with a low level of education, only 
patients who had received at least 9 years of education (mid-
dle-school graduate) were enrolled in this study.
We received approval for human experimentation from 
the Institutional Review Board at the hospital (Approval No. 
CR315007), and written informed consent was obtained 
from all subjects participating in this study.
Cognitive assessment
The cognitive assessments were conducted by experienced 
neuropsychologists using the following tests in order to fulfill 
the Level II criteria for PD-MCI11 proposed by the Movement 
Disorders Society (MDS): forward digit span12 and trail-mak-
ing test type A (TMT-A)12 for the attention domain, the Ko-
rean version of the Boston Naming Test (K-BNT)12 and simi-
larity test of the Wechsler Adult Intelligence Scale-Fourth 
Edition13 for language function, the copying task of the Rey-
Osterrieth Complex Figure Test (RCFT)12 and clock copying 
(CLOX2)14 for visuospatial function, 20-min delayed recall 
using the Seoul Verbal Learning Test (SVLT)12 and 20-min 
delayed recall using the RCFT12 for the memory domain, 
semantic fluency (animal) using the Controlled Oral Word 
Association Test,12 and the clock-drawing test for executive 
function. The Korean version of the Mini Mental State Ex-
amination (K-MMSE),15 Korean version of the Montreal Cog-
nitive Assessment (K-MoCA),16 and self-rated Beck Depres-
sion Inventory (BDI) were used to assess general cognition 
and depressive symptoms in the subjects.
Assessment of SCCs using the CCI
The subjective self-perceived cognitive function of the sub-
jects was assessed using the CCI17 just before they completed 
a comprehensive neuropsychological assessment. The ques-
tions from the CCI were translated into Korean by the in-
vestigators and provided to subjects on paper. The subjects 
were asked to read the questions and answer as either “yes” 
or “no.” The CCI score was calculated as the number of ques-
tions to which the subjects responded “yes” to.
Diagnosis of MCI and dementia 
MCI was diagnosed according to the following Level II cri-
teria for PD-MCI proposed by the MDS:11 1) performance 
in at least 2 of the 10 subtests was lower than the mean mi-
nus 1.5×standard deviations of the normative data corrected 
for age and level of education and 2) activities of daily living 
(ADL) were not impaired. 
Dementia was diagnosed according to the following crite-
ria proposed by the MDS:18 1) the mean z score of two tests 
for each cognitive domain was lower than -1.5 in at least two 
domains and 2) impaired ADL.
Statistical analysis
One-way analysis of variance and the chi-square test were 
used to compare groups, with the Bonferroni method used 
for post hoc analyses. The Kuder-Richardson Formula 20 
(KR-20) coefficient was calculated to verify the internal con-
sistency of the CCI. We used multivariate linear regression 
models and calculated partial correlation coefficients to ad-
just for the confounding factors influencing the relationship 
between the CCI score and cognitive performance. Receiver 
operating characteristics (ROC) curves were drawn to test 
the discriminative value of the CCI score. Statistical analyses 
were performed using SPSS Statistics (version 23, IBM Corp., 
Armonk, NY, USA), and p<0.05 was considered significant. 
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RESUlTS 
Subjects and baseline demographics
In total, 250 patients with PD (150 males and 100 females) 
were recruited for this study, and they were classified into 
cognitively normal (CN, n=148), MCI (n=71), and dementia 
(D, n=31) groups based on neuropsychological assessments. 
The subjects in group D were older and had a longer dura-
tion of PD and higher Unified Parkinson’s Disease Rating 
Scale (UPDRS) motor score than those in group CN, and 
both groups MCI and D had a higher levodopa equivalent 
daily dose (LEDD) and BDI score than group CN (Table 1). 
There were no differences in sex, age at onset of PD, or level 
of education among the groups.
Neuropsychological performance
The findings for the neuropsychological performance of the 
subjects are presented in Supplementary Table 1 (in the on-
line-only Data Supplement). Groups CN and MCI showed 
better performance in all tests compared to group D. Groups 
CN and MCI performed comparably in the TMT-A, while 
group CN performed better than MCI group in all of the oth-
er tests.
The CCI score was lowest in group CN and highest in group 
D (Fig. 1). Significant differences were observed among the 
groups.
Internal consistency of the CCI
The KR-20 coefficient of the CCI was 0.78, and the coeffi-
cients for corrected item-total correlation were greater than 
0.25 (p<0.001) for all items of the CCI.
Correlation between the CCI score and 
neuropsychological performance
The CCI score was strongly correlated with the scores in all 
of the neuropsychological performance tests (Table 2), and 
also correlated with other factors including age (r=0.145, 
p=0.022), duration of PD (r=0.158, p=0.013), LEDD (r=0.338, 
p=0.003), and BDI score (r=0.527, p<0.001).
When the model was adjusted for the BDI score (model 
1 in Table 2), the CCI score was significantly correlated with 
the K-MMSE score, K-MoCA score, and performance in the 
TMT-A, K-BNT, copying task of the RCFT, delayed recall in 
both the SVLT and RCFT, and clock-drawing test. The other 
demographic factors including age, sex, duration of PD, and 
level of education (model 2 in Table 2) did not influence the 
significance of the correlation between the CCI and cogni-
tive performance found in model 1.
Discriminative value of the CCI score
ROC curves were drawn to evaluate the discriminative pow-
er of the CCI score (Fig. 2).
The CCI score could be used to discriminate group D from 
groups CN and MCI [area under the ROC curve (AUC)=0.80, 
95% confidence interval (CI)=0.72–0.88]. The optimal screen-
ing cutoff was a CCI score of ≥5 (sensitivity and specificity of 
0.84 and 0.66, respectively), and the optimal diagnostic cutoff 
was a CCI score of ≥7 (sensitivity and specificity of 0.58 and 
0.83, respectively).
Table 1. Demographic characteristics of subjects classified according to cognitive status
Variables CN (n=148) MCI (n=71) D (n=31) p Significant differences
Sex (male/female) 84/64 45/26 21/10 0.415
Age (years) 68.2±7.9 70.0±8.7 73.6±7.2 0.003 CN<D
Age at onset of PD (years) 64.4±8.7 64.9±10.8 67.7±9.0 0.215
Duration of PD (years) 3.8±3.6 5.1±4.8 5.9±4.9 0.008 CN<D
UPDRS motor score 22.3±10.8 27.6±10.1 32.6±11.8 0.004 CN<D
LEDD (mg/day) 298.6±298.7 642.2±535.4 736.8±342.1 <0.001 CN<MCI, D
Level of education (years) 12.3±2.9 12.8±3.0 13.3±3.3 0.171
BDI score 11.1±7.9 15.7±10.3 18.3±11.2 <0.001 CN<MCI, D
Data are mean±standard-deviation values.
BDI: Beck Depression Inventory, CN: cognitively normal, D: dementia, LEDD: levodopa equivalent daily dose, MCI: mild cognitive impairment, PD: Par-
kinson’s disease, UPDRS: Unified Parkinson’s Disease Rating Scale.
Fig. 1. Proportions of CCI scores in the three cognitive groups. CCI: 
Cognitive Complaints Interview, CN: cognitively normal, D: dementia, 
MCI: mild cognitive impairment.
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However, the CCI score could not be used to discriminate 
group MCI or D from group CN (AUC=0.67, 95% CI=0.60–
0.74).
DISCUSSION
The present results show that the severity of SCCs as mea-
sured by the CCI is correlated with objective cognitive im-
pairment. The CCI can also be used for screening dementia in 
Table 2. Correlation between CCI score and neuropsychological performance
Variables
Pearson’s correlation Model 1 Model 2
r p Partial r p Partial r p
Age 0.145 0.022
Age at onset of PD 0.056 0.374
Duration of PD 0.158 0.013
UPDRS motor score 0.142 0.166
LEDD 0.338 0.003
Level of education -0.084 0.188
K-MMSE score -0.370 <0.001 -0.270 <0.001 -0.221 0.001
K-MoCA score -0.339 <0.001 -0.223 <0.001 -0.168 0.008
Forward digit span -0.220 <0.001 -0.120 0.058 -0.078 0.227
TMT-A score 0.258 <0.001 0.191 0.003 0.150 0.020
K-BNT score -0.345 <0.001 -0.239 <0.001 -0.205 0.001
Word similarity -0.164 0.010 -0.011 0.863 0.025 0.693
Copying task of RCFT -0.386 <0.001 -0.271 <0.001 -0.236 <0.001
Clock copying (CLOX2) -0.206 0.001 -0.125 0.050 -0.089 0.169
Delayed recall in SVLT -0.352 <0.001 -0.239 <0.001 -0.179 0.005
Delayed recall in RCFT -0.345 <0.001 -0.212 0.001 -0.166 0.009
Semantic fluency (animal) -0.230 <0.001 -0.106 0.095 -0.043 0.507
Clock-drawing test -0.311 <0.001 -0.253 <0.001 -0.220 0.001
BDI 0.527 <0.001
Model 1: adjusted for BDI score, Model 2: adjusted for BDI score, age, sex, duration of PD, and level of education, r: correlation coefficient.
BDI: Beck Depression Inventory, CCI: Cognitive Complaints Interview, LEDD: levodopa equivalent daily dose, K-BNT: Korean version of the Boston Nam-
ing Test, K-MMSE: Korean version of the Mini Mental State Examination, K-MoCA: Korean version of the Montreal Cognitive Assessment, PD: Parkin-
son’s disease, RCFT: Rey-Osterrieth Complex Figure Test, SVLT: Seoul Verbal Learning Test, TMT-A: trail-making test type A.
Fig. 2. ROC curves for discriminating (A) group MCI or D from group CN, and (B) group D from group CN or MCI, AUC, area under the ROC curve. 
CN: cognitively normal, D: dementia, MCI: mild cognitive impairment, ROC: receiver operating characteristics.
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patients with PD.
SCCs were more prominent when the cognitive status 
was lower in this study. There were more cognitive com-
plaints in group MCI than in group CN, and the CCI score 
was highest in group D. A relationship between cognitive 
impairment and SCCs indexes has been consistently report-
ed in patients without PD. Recent validation studies found 
that scores were higher in patients with MCI or dementia due 
to AD than in cognitively normal subjects.19,20 Previous studies 
of patients with PD also found a significant relationship be-
tween SCCs and cognitive impairment. Two studies showed 
an inverse correlation between the SMCs score and cognitive 
performance in nondemented PD patients.5,7 Two other stud-
ies found a relationship between lower visuospatial or exec-
utive function and the presence of SCCs in cognitively normal 
patients with PD.6,21 Consistent with previous studies, the pres-
ent results also demonstrated that a higher SCCs score is strong-
ly correlated with worse performance in many cognitive sub-
tests.
All previous studies have assessed SCCs using a simple 
yes/no question or questionnaire for SMCs, and so the pres-
ent study is the first to assess SCCs using an ordinal scale, 
which revealed a significant correlation with objective cogni-
tive performance. SCCs in patients with AD focus on memory 
function because memory impairment is the most common 
and earliest manifestation of AD. However, this is not the es-
sential component of cognitive impairment in patients with 
PD–executive dysfunction is actually the characteristic fea-
ture and predictor of developing dementia in PD-MCI.22 
Therefore, the CCI including questions on cognitive abilities 
other than memory function seems to be more suitable for 
assessing SCCs in patients with PD, and its scores were strongly 
correlated with objective cognitive performance in this study. 
However, the value of such questions in assessing cognitive 
function other than memory needs to be verified in a longi-
tudinal study. Also, the most appropriate questions need to 
be determined in order to develop a better tool for measur-
ing SCCs in patients with PD. 
The average CCI score increased gradually with cognitive 
decline in the present study. Both the score distribution (Fig. 
1) and discriminating power (Fig. 2) indicated that the dif-
ference was more prominent between patients with demen-
tia and MCI. In previous studies that included patients with 
dementia and MCI due to AD, the SCCs scores were higher in 
MCI patients than in cognitively normal control subjects, with 
demented patients showing similar or lower scores than MCI 
patients. The authors supposed that the higher SCCs score in 
MCI patients than control may be a reflection of self-aware-
ness for cognitive dysfunction, with the lower SCCs score of de-
mented patients being due to their deterioration of awareness. 
Unlike AD, the subjective feeling of cognitive impairment in 
patients with PD seems to be maintained by their demented 
status, which suggests that the underlying pathophysiological 
mechanisms of SCCs in patients with PD may differ from that 
of AD.
SCCs are well known to be related to psychological prob-
lems, especially depression. The BDI score was strongly cor-
related with the CCI score in the present study, and so re-
gression models were used to adjust for the BDI score. This 
adjustment reduced the strength of the correlation between 
cognitive performance and CCI score, while the correlations 
in many subtests including the K-MMSE and K-MoCA re-
mained significant. Depression is a very common nonmotor 
symptom in patients with PD, and the incidence rates of both 
depression and cognitive impairment increase with the dis-
ease progression. The present data also revealed a strong cor-
relation between BDI and CCI scores; however, further inves-
tigations are needed into the causal relationship between 
depression and SCCs.
The present results show that the CCI score is useful for 
discriminating dementia from normal cognition or MCI. A 
previous study using the CCI in patients with PD found that 
this metric had insufficient power to screen for PD-associat-
ed dementia (AUC=0.69).17 This discrepancy may have 
been due to differences in cognitive assessment methods 
and diagnostic criteria for dementia. That previous study di-
vided patients into cognitively normal and impaired groups, 
while the present study classified subjects into cognitively nor-
mal, MCI, and dementia groups. The CCI score could be used 
to distinguish between demented and nondemented patients 
in present study, and so the heterogeneity in the cognitively 
impaired group of the previous study could have weakened the 
discriminant power of the CCI.
This study was subject to several limitations. First, the 
cross-sectional design meant that longitudinal changes in 
cognition could not be predicted, and so a future long-term 
study is needed to expand on the clinical implications of the 
CCI. Second, selection bias may have been present since this 
study involved a patient population from a tertiary referral 
hospital. Finally, this study did not include pathological data. 
Because AD pathology was also observed in patients with 
PD,23,24 it is possible that AD pathology was intermixed with 
PD pathology in the present subjects.
In summary, SCCs as measured by the CCI are strongly 
correlated with objective cognitive performance in patients 
with PD. In addition, the CCI can be used to screen for de-
mentia in patients with PD. 
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